Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nubeqa in high-risk non-metastatic castration-resistant prostate cancer
NCT02200614Phase 3Completed
- Sponsor
- Bayer
- Start
- Sep 2014
- Primary completion
- Sep 2018
- Countries
- 36
01
Overview
A Phase 3 trial of darolutamide in prostate cancer (PCa), sponsored by Bayer. Started Sep 2014; status: completed.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02200614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02200614.